Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENC·NASDAQ

$9.35

-6.3%
HealthcareBiotechnology

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

At a Glance

Live Snapshot
Market Cap$267.13M
EPS-0.3600
P/E Ratio-25.96
Earnings Date08/13/2026

fenc

Net Change in Cash

Last Annual Value

10.15M

3-Year CAGR

56%

5-Year CAGR

-9%

10-Year CAGR

25%

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. Competitors Analysis of Net Change in Cash

FENC · NASDAQ
CompanyNet Change in Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
10.15M
N/AN/A13.0% 
12.43M
4.9%N/AN/A
-15.44M
N/AN/AN/A
20.11M
N/AN/A29.9%
92.50M
N/A19.6%N/A
57.91M
N/AN/AN/A
-40.82M
N/AN/AN/A
-10.82M
N/AN/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
-67.09M
N/AN/AN/A
-3.93M
N/AN/AN/A
-87.41M
N/AN/AN/A
Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. Fair Value Envelope

FENC · NASDAQ

Our analysis suggests that FENC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.3467, this represents a potential HIDDEN relative to our calculated worth for Fennec Pharmaceuticals Inc..

Intrinsic Value
Current Price: $9.3467